We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+10.27%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$22.8B
AUM Growth
-$510M
Cap. Flow
-$2.26B
Cap. Flow %
-9.9%
Top 10 Hldgs %
40.08%
Holding
187
New
21
Increased
43
Reduced
39
Closed
22

Top Buys

Rank Stock Value
1
DIS icon
Walt Disney
DIS
+$207M
2
ANSS
Ansys
ANSS
+$201M
3
WWD icon
Woodward
WWD
+$192M
4
SWN
Southwestern Energy Company
SWN
+$168M
5
SQSP
Squarespace, Inc.
SQSP
+$130M

Top Sells

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$294M
2
NDAQ icon
Nasdaq
NDAQ
+$256M
3
CRM icon
Salesforce
CRM
+$231M
4
AZN icon
AstraZeneca
AZN
+$188M
5
ARMK icon
Aramark
ARMK
+$187M

Sector Composition

Rank Sector Weight
1 Healthcare 31.84%
2 Technology 13.48%
3 Financials 9.84%
4 Communication Services 6.79%
5 Industrials 6.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ONC
126
BeOne Medicines Ltd
ONC
$39.4B
$247K ﹤0.01%
+1,100
New +$198K
IOVA icon
127
Iovance Biotherapeutics
IOVA
$2.87B
$244K ﹤0.01%
26,000
– –
ARQT icon
128
Arcutis Biotherapeutics
ARQT
$3.18B
$242K ﹤0.01%
26,000
– –
CHE icon
129
Chemed
CHE
$7.22B
$240K ﹤0.01%
400
– –
HIMS icon
130
Hims & Hers Health
HIMS
$7.31B
$239K ﹤0.01%
13,000
+3,000
+30% +$53.7K
ELAN icon
131
Elanco Animal Health
ELAN
$11.1B
$235K ﹤0.01%
+16,000
New +$223K
OSCR icon
132
Oscar Health
OSCR
$8.61B
$233K ﹤0.01%
11,000
– –
RNAM
133
DELISTED
Avidity Biosciences
RNAM
$230K ﹤0.01%
5,000
– –
PACB icon
134
Pacific Biosciences
PACB
$370M
$230K ﹤0.01%
135,000
– –
HQY icon
135
HealthEquity
HQY
$8.75B
$229K ﹤0.01%
2,800
– –
RCM
136
DELISTED
R1 RCM Inc. Common Stock
RCM
$227K ﹤0.01%
16,000
– –
RARE icon
137
Ultragenyx Pharmaceutical
RARE
$2.55B
$222K ﹤0.01%
4,000
-95,000
-96% -$4.84M
INSM icon
138
Insmed
INSM
$28.6B
$219K ﹤0.01%
3,000
-565,000
-99% -$41.7M
ASND icon
139
Ascendis Pharma A/S
ASND
$16.8B
$209K ﹤0.01%
+1,400
New +$189K
NVAX icon
140
Novavax
NVAX
$1.31B
$202K ﹤0.01%
16,000
-361,250
-96% -$4.66M
GERN icon
141
Geron
GERN
$949M
$195K ﹤0.01%
43,000
-16,794,000
-100% -$76.4M
SNDX icon
142
Syndax Pharmaceuticals
SNDX
$1.82B
$193K ﹤0.01%
10,000
– –
COGT icon
143
Cogent Biosciences
COGT
$7.24B
$184K ﹤0.01%
17,000
-408,161
-96% -$3.97M
FOLD
144
DELISTED
Amicus Therapeutics
FOLD
$171K ﹤0.01%
16,000
– –
ALT icon
145
Altimmune
ALT
$599M
$169K ﹤0.01%
27,600
– –
CCCC icon
146
C4 Therapeutics
CCCC
$412M
$160K ﹤0.01%
28,000
– –
ARDX icon
147
Ardelyx
ARDX
$997M
$158K ﹤0.01%
23,000
– –
CGC
148
Canopy Growth
CGC
$410M
$145K ﹤0.01%
30,000
– –
BYND icon
149
Beyond Meat
BYND
$277M
$129K ﹤0.01%
19,000
– –
SEDA.WS
150
DELISTED
SDCL EDGE Acquisition Corporation Redeemable warrants, each whole warrant exercisable for one share of Class A ordinary share at an exercise price of $11.50
SEDA.WS
$86.6K ﹤0.01%
866,250
– –
4 5
6
7 8

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Farallon Capital Management held 187 positions worth $22.8B, down 2.2% from $23.3B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Farallon Capital Management withdrew a net $2.26B in Q3 2024, closing 22 positions and reducing 39 holdings. Its most notable exit was AstraZeneca, an estimated $188M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 29% a quarter earlier, followed by Technology and Financials.

Against the trend, Farallon Capital Management opened a new position in Woodward worth $198M.

  • Farallon Capital Management's largest Q3 2024 buy was Woodward: 1,154,000 shares worth $198M.
  • Farallon Capital Management added most to Walt Disney in Q3 2024, an estimated $207M increase.
  • Farallon Capital Management's biggest Q3 2024 reduction was UnitedHealth, cutting an estimated $294M.
  • Farallon Capital Management fully exited AstraZeneca in Q3 2024, selling an estimated $188M.
  • Farallon Capital Management's ten largest holdings make up 40% of its $22.8B portfolio in Q3 2024.
  • Farallon Capital Management opened 21 new positions and closed 22 in Q3 2024.
  • Farallon Capital Management's portfolio value fell 2.2% quarter-over-quarter to $22.8B.

Based on Farallon Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.